Enhancing immunity to tuberculosis
The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.
1. A hybridoma cell line deposited with ATCC as Accession No. PTA-124416.
2. A monoclonal antibody expressed by the hybridoma cell line of claim 1 .
3. A hybridoma cell line deposited with ATCC as Accession No. PTA-124417.
4. A monoclonal antibody expressed by the hybridoma cell line of claim 3 .
5. A hybridoma cell line deposited with ATCC as Accession No. PTA-124418.
6. A monoclonal antibody expressed by the hybridoma cell line of claim 5 .
7. An Fc or variable region of the monoclonal antibody of claim 2 .
8. An Fc or variable region of the monoclonal antibody of claim 4 .
9. An Fc or variable region of the monoclonal antibody of claim 6 .
10. A CDR of the monoclonal antibody of claim 2 .
11. A CDR of the monoclonal antibody of claim 4 .
12. A CDR of the monoclonal antibody of claim 6 .
13. A peptide of the monoclonal antibody of claim 2 .
14. A peptide of the monoclonal antibody of claim 4 .
15. A peptide of the monoclonal antibody of claim 6 .
16. A fully or partly humanized antibody derived from the monoclonal antibody of claim 2 .
17. A fully or partly humanized antibody derived from the monoclonal antibody of claim 4 .
18. A fully or partly humanized antibody derived from the monoclonal antibody of claim 6 .